Roman Kasianov

Oracle has launched a new electronic health record (EHR) platform that diverges entirely from the architecture of Cerner, which it acquired in 2022 for $28 billion. As reported by CNBC, the platform is browser-based, cloud-native, and designed to support AI-driven workflows, including voice queries, ambient documentation, and clinician-adaptive interfaces.

As reported by The Quantum Insider, Kvantify, a Denmark-based quantum software firm focused on chemistry and drug discovery, has become the first dedicated quantum company to deploy the Gefion AI supercomputer for simulating quantum computing workflows at scale. While Gefion was originally built for large-scale AI workloads, its GPU-accelerated architecture is being repurposed by Kvantify to run proprietary algorithms for molecular modeling and enzyme engineering.

Valinor Discovery, a San Francisco-based startup, has launched from stealth to build generative machine learning models that simulate how patients may respond to therapies—prior to any clinical testing. These models are trained on matched multi-omics and clinical assay data derived from individual patients, with initial applications in oncology aimed at predicting treatment response to cancer therapeutics.

The company’s second Phase 1b/2 trial of LP-184 within a month will test the AI-developed small molecule in patients with lung tumors that resist standard treatments.

OpenAI has released HealthBench, an open-source benchmark developed with 262 physicians across 60 countries to evaluate large language models (LLMs) in realistic healthcare interactions. The benchmark includes 5,000 multilingual, multi-turn conversations involving both individual users and healthcare professionals, each paired with a unique rubric constructed by medical experts. In total, HealthBench comprises 48,562 distinct evaluation criteria.

Toronto-based Intrepid Labs has emerged from stealth with $11 million in total funding to commercialize its autonomous drug formulation platform, Valiant. Designed to overhaul conventional formulation workflows, Valiant combines machine learning, real-time experiment planning, and robotic execution to optimize delivery strategies for small molecules and biologics.

At the 2025 Annual Meeting of the American Association for Cancer Research (AACR)—a major international conference focused on cancer science and therapeutic development—Crown Bioscience, a preclinical contract research organization specializing in oncology and immuno-oncology, announced the launch of its 3D Bone Marrow Niche (BMN) platform.

Milan-based startup ReportAId has raised €2.2 million in pre-seed funding to develop its AI platform aimed at converting unstructured medical reports into structured, actionable care plans. The round was led by Italian Founders Fund, with participation from Heartfelt, Exceptional Ventures, 2100 Ventures, Vento, Ithaca, B Heroes, Vesper Holding, and several angel investors.

North Bristol NHS Trust has been named the first European reference site for FUJIFILM Healthcare’s SYNAPSE Pathology system, marking a continuation of their collaboration that began in 2022. The agreement designates the Trust as a demonstration and development partner for FUJIFILM’s digital pathology technologies, including the SYNAPSE Pathology Gateway.

The collaboration aims to address rising histopathology workloads across the UK, with projections from Cancer Research UK indicating a 47% increase in demand by 2029. FUJIFILM and North Bristol plan to further develop and validate the platform for wider use across NHS sites and European healthcare institutions.

Inductive Bio has secured $25 million in Series A financing to expand its machine learning platform for small molecule drug discovery. The round was led by Obvious Ventures, with participation from Andreessen Horowitz Bio + Health, Lux Capital, S32, Character, Amino Collective, and several angel investors including Oren Etzioni and Jakob Uszkoreit.

Proceeds from the Series A will support continued development of the consortium dataset, new model iterations, and plans to layer the offering into an AI-native contract research organization (CRO).